Quest Diagnostics Expands Lab Access via Apple Health App for U.S. Consumers

Quest Diagnostics has launched a noteworthy expansion in consumer access this week, enabling U.S. users of Apple’s Health app to purchase laboratory tests directly within the app for $119. The announcement marks a strategic push into consumer-facing diagnostics and further integration of Quest’s services into digital health platforms.

According to a report by Investing.com published on September 9, 2026, U.S. users of the Apple Health app are now able to order Quest Diagnostics lab tests for $119 on the spot. This new feature places Quest’s testing services within immediate reach of iPhone users, streamlining access and enhancing convenience for consumers.

This development directly involves Quest Diagnostics (DGX), a key player in the diagnostic information services space, and aligns with broader digital health trends reshaping consumer access to medical testing. By embedding lab-ordering capabilities into a widely used mobile app, Quest seeks to capture a growing segment of direct-to-consumer healthcare demand.

The launch could meaningfully broaden Quest’s consumer market reach and reflects the company’s continued evolution beyond traditional lab service models. While no immediate effect on Quest’s share price has been substantiated, this innovation may support future testing volumes and consumer engagement metrics over time.

The current verified share price of DGX is $228.39, slightly down by 0.67% as of October 6, 2026. This figure reflects the latest available market data and is presented without assuming a causal connection to the app launch.

Looking ahead, investors and market watchers may monitor user adoption of in-app lab orders, any volumes disclosed by Quest Diagnostics, and potential follow-through from this consumer integration to assess its longer-term financial impact.